{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:54:43Z","timestamp":1781639683987,"version":"3.54.5"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Dutch Research Council","doi-asserted-by":"crossref","award":["KICH1.ST01.20.011"],"award-info":[{"award-number":["KICH1.ST01.20.011"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acute kidney injury (AKI) is a common and severe complication in hospitalized patients. Nephrotoxic drugs significantly contribute to AKI. Diagnosis and prevention of drug-induced AKI (d-AKI) could be improved, but little is known about its occurrence despite preventive efforts. Therefore, the objective of this study was to investigate hospital physicians\u2019 reasoning about d-AKI and gain insight into the challenges they encounter, including identifying unmet information needs surrounding d-AKI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted semi-structured interviews with hospital physicians from diverse specialties and experience levels at one Dutch academic hospital. Two interviews were independently open coded by 3 researchers and the resulting codes\/themes organized by consensus. Using the resulting code tree, we conducted thematic analysis of the interviews.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirteen interviews were conducted (6 women, 7 men), with physicians\u2019 professional experience ranging from 3 to 36 years. The group comprised 9 specialists and 4 residents. For many of these physicians, managing AKI takes priority over diagnosing d-AKI. AKI cases with multifactorial etiology and limited d-AKI awareness were mentioned as reasons for delay in or lack of d-AKI diagnosis. Physicians emphasized monitoring and risk assessment with regards to d-AKI prevention. While kidney function is generally well-monitored during hospitalization, there are circumstances where the urgency of treatment may result in less weight on nephrotoxic potential. Physicians expressed the need for an up-to-date home medication overview, monitoring guidance around nephrotoxic drugs, and better prediction of d-AKI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study highlights key aspects of current hospital practices surrounding d-AKI. Diagnosing d-AKI often has a low priority, which may explain why it is often underdiagnosed and not registered. Prevention is limited by gaps in monitoring and the need for nephrotoxic drugs in urgent situations. We emphasize the need for improved d-AKI diagnosis and clinical awareness, and providing personalized d-AKI prevention strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-026-04852-x","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T11:33:10Z","timestamp":1772623990000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hospital physicians\u2019 reasoning and information needs in the diagnosis and prevention of drug-induced acute kidney injury: a qualitative study"],"prefix":"10.1186","volume":"27","author":[{"given":"Joris E.","family":"Lieverse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyrill N. A.","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Dusseljee-Peute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna E.","family":"Klopotowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Medlock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the LEAPfROG Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"issue":"9","key":"4852_CR1","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.2215\/CJN.00710113","volume":"8","author":"P Susantitaphong","year":"2013","unstructured":"Susantitaphong P, Cruz DN, Cerda J, Abulfaraj M, Alqahtani F, Koulouridis I, et al. World incidence of AKI: a meta-analysis. Clin J Am Soc Nephrol. 2013;8(9):1482\u201393.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"4852_CR2","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1177\/0897190019852556","volume":"32","author":"JF Dasta","year":"2019","unstructured":"Dasta JF, Kane-Gill S. Review of the Literature on the Costs Associated With Acute Kidney Injury. J Pharm Pract. 2019;32(3):292\u2013302.","journal-title":"J Pharm Pract"},{"issue":"4","key":"4852_CR3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/cpt.3493","volume":"117","author":"BA Stottlemyer","year":"2025","unstructured":"Stottlemyer BA, Tran T, Suh K, Kane-Gill SL. A Systematic Review of the Costs of Drug-Associated Acute Kidney Injury and Potential Cost Savings With Nephrotoxin Stewardship Prevention Strategies. Clin Pharmacol Ther. 2025;117(4):989\u20131004.","journal-title":"Clin Pharmacol Ther"},{"key":"4852_CR4","doi-asserted-by":"publisher","first-page":"1459170","DOI":"10.3389\/fmed.2024.1459170","volume":"11","author":"G Garcia","year":"2024","unstructured":"Garcia G, Pacchini VR, Zamoner W, Balbi AL, Ponce D. Drug-induced acute kidney injury: a cohort study on incidence, identification of pathophysiological mechanisms, and prognostic factors. Front Med (Lausanne). 2024;11:1459170.","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"4852_CR5","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00134-015-3934-7","volume":"41","author":"EA Hoste","year":"2015","unstructured":"Hoste EA, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015;41(8):1411\u201323.","journal-title":"Intensive Care Med"},{"issue":"7","key":"4852_CR6","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1001\/jama.294.7.813","volume":"294","author":"S Uchino","year":"2005","unstructured":"Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, et al. Acute Renal Failure in Critically Ill PatientsA Multinational, Multicenter Study. JAMA. 2005;294(7):813\u20138.","journal-title":"JAMA"},{"issue":"2","key":"4852_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1159\/000510455","volume":"7","author":"C Liu","year":"2021","unstructured":"Liu C, Yan S, Wang Y, Wang J, Fu X, Song H, et al. Drug-Induced Hospital-Acquired Acute Kidney Injury in China: A Multicenter Cross-Sectional Survey. Kidney Dis (Basel). 2021;7(2):143\u201355.","journal-title":"Kidney Dis (Basel)"},{"issue":"1","key":"4852_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40264-024-01474-w","volume":"48","author":"D Fern\u00e1ndez-Llaneza","year":"2025","unstructured":"Fern\u00e1ndez-Llaneza D, Vos RMP, Lieverse JE, Gosselt HR, Kane-Gill SL, van Gelder T, et al. An Integrated Approach for Representing Knowledge on the Potential of Drugs to Cause Acute Kidney Injury. Drug Saf. 2025;48(1):43\u201358.","journal-title":"Drug Saf"},{"issue":"4","key":"4852_CR9","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1177\/10600280241273191","volume":"59","author":"EF Barreto","year":"2025","unstructured":"Barreto EF, Gaggani AM, Hernandez BN, Amatullah N, Culley CM, Stottlemyer B, et al. The Acute Kidney Intervention and Pharmacotherapy (AKIP) List: Standardized List of Medications That Are Renally Eliminated and Nephrotoxic in the Acutely Ill. Ann Pharmacother. 2025;59(4):371\u20137.","journal-title":"Ann Pharmacother"},{"issue":"7","key":"4852_CR10","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1093\/ndt\/gfz023","volume":"34","author":"C Zoccali","year":"2019","unstructured":"Zoccali C, Blankestijn PJ, Bruchfeld A, Capasso G, Fliser D, Fouque D, et al. Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials. Nephrol Dial Transpl. 2019;34(7):1112\u20134.","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"4852_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/1740774516673818","volume":"14","author":"JJ Gagne","year":"2017","unstructured":"Gagne JJ, Khan NF, Raj TS, Patel LR, Choudhry NK. Strength of evidence for labeled dosing recommendations in renal impairment. Clin Trials. 2017;14(2):219\u201321.","journal-title":"Clin Trials"},{"issue":"12","key":"4852_CR12","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1159\/000531916","volume":"147","author":"N Amatullah","year":"2023","unstructured":"Amatullah N, Stottlemyer BA, Zerfas I, Stevens C, Ozrazgat-Baslanti T, Bihorac A, et al. Challenges in Pharmacovigilance: Variability in the Criteria for Determining Drug-Associated Acute Kidney Injury in Retrospective, Observational Studies. Nephron. 2023;147(12):725\u201332.","journal-title":"Nephron"},{"issue":"10","key":"4852_CR13","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s40266-017-0484-4","volume":"34","author":"S Khan","year":"2017","unstructured":"Khan S, Loi V, Rosner MH. Drug-Induced Kidney Injury in the Elderly. Drugs Aging. 2017;34(10):729\u201341.","journal-title":"Drugs Aging"},{"issue":"2","key":"4852_CR14","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1177\/1751143719900099","volume":"22","author":"S Tominey","year":"2021","unstructured":"Tominey S, Timmins A, Lee R, Walsh TS, Lone NI. Community prescribing of potentially nephrotoxic drugs and risk of acute kidney injury requiring renal replacement therapy in critically ill adults: A national cohort study. J Intensive Care Soc. 2021;22(2):102\u201310.","journal-title":"J Intensive Care Soc"},{"issue":"7","key":"4852_CR15","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.2215\/CJN.11921112","volume":"8","author":"ZL Cox","year":"2013","unstructured":"Cox ZL, McCoy AB, Matheny ME, Bhave G, Peterson NB, Siew ED, et al. Adverse drug events during AKI and its recovery. Clin J Am Soc Nephrol. 2013;8(7):1070\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"4852_CR16","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s40264-014-0160-0","volume":"37","author":"JC van Blijderveen","year":"2014","unstructured":"van Blijderveen JC, Straus SM, de Ridder MA, Stricker BH, Sturkenboom MC, Verhamme KM. Adherence to renal function monitoring guidelines in patients starting antihypertensive therapy with diuretics and RAAS inhibitors: a retrospective cohort study. Drug Saf. 2014;37(5):369\u201377.","journal-title":"Drug Saf"},{"issue":"1","key":"4852_CR17","doi-asserted-by":"publisher","first-page":"e011765","DOI":"10.1136\/bmjopen-2016-011765","volume":"7","author":"DL Phipps","year":"2017","unstructured":"Phipps DL, Morris RL, Blakeman T, Ashcroft DM. What is involved in medicines management across care boundaries? A qualitative study of healthcare practitioners\u2019 experiences in the case of acute kidney injury. BMJ Open. 2017;7(1):e011765.","journal-title":"BMJ Open"},{"issue":"1","key":"4852_CR18","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12911-020-01303-x","volume":"20","author":"M Howarth","year":"2020","unstructured":"Howarth M, Bhatt M, Benterud E, Wolska A, Minty E, Choi KY, et al. Development and initial implementation of electronic clinical decision supports for recognition and management of hospital-acquired acute kidney injury. BMC Med Inf Decis Mak. 2020;20(1):287.","journal-title":"BMC Med Inf Decis Mak"},{"issue":"1","key":"4852_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40780-025-00431-8","volume":"11","author":"A Sonoda","year":"2025","unstructured":"Sonoda A. A clinical decision support system promotes the appropriate use of drugs in hospitalized patients with kidney impairment. J Pharm Health Care Sci. 2025;11(1):26.","journal-title":"J Pharm Health Care Sci"},{"issue":"1","key":"4852_CR20","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2215\/CJN.13841217","volume":"14","author":"M Martin","year":"2019","unstructured":"Martin M, Wilson FP. Utility of Electronic Medical Record Alerts to Prevent Drug Nephrotoxicity. Clin J Am Soc Nephrol. 2019;14(1):115\u201323.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"4852_CR21","doi-asserted-by":"publisher","first-page":"e438","DOI":"10.1111\/hsc.12744","volume":"27","author":"A Haase","year":"2019","unstructured":"Haase A, Stracke S, Chenot JF, Weckmann G. Nephrologists\u2019 perspectives on ambulatory care of patients with non-dialysis chronic kidney disease - A qualitative study. Health Soc Care Community. 2019;27(4):e438\u201348.","journal-title":"Health Soc Care Community"},{"issue":"3","key":"4852_CR22","doi-asserted-by":"publisher","first-page":"e010337","DOI":"10.1136\/bmjopen-2015-010337","volume":"6","author":"R Simmonds","year":"2016","unstructured":"Simmonds R, Evans J, Feder G, Blakeman T, Lasserson D, Murray E, et al. Understanding tensions and identifying clinician agreement on improvements to early-stage chronic kidney disease monitoring in primary care: a qualitative study. BMJ Open. 2016;6(3):e010337.","journal-title":"BMJ Open"},{"issue":"1","key":"4852_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/ckj\/sfv130","volume":"9","author":"NS Kanagasundaram","year":"2016","unstructured":"Kanagasundaram NS, Bevan MT, Sims AJ, Heed A, Price DA, Sheerin NS. Computerized clinical decision support for the early recognition and management of acute kidney injury: a qualitative evaluation of end-user experience. Clin Kidney J. 2016;9(1):57\u201362.","journal-title":"Clin Kidney J"},{"issue":"2","key":"4852_CR24","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/bcp.15928","volume":"90","author":"MA Alanzi","year":"2024","unstructured":"Alanzi MA, Tully MP, Lewis PJ. Exploring the challenges faced by foundation doctors when prescribing high risk medicines safely during the on-call period: A qualitative study. Br J Clin Pharmacol. 2024;90(2):548\u201356.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"4852_CR25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349\u201357.","journal-title":"Int J Qual Health Care"},{"key":"4852_CR26","unstructured":"PharmacoInformatics Lab - LEAPfROG project. Accessed May 27. 2025. [Available from: https:\/\/www.pharmacoinformaticslab.nl\/en\/leapfrog\/"},{"key":"4852_CR27","unstructured":"Microsoft Teams. Accessed May 27. 2025.: https:\/\/www.microsoft.com\/en-us\/microsoft-teams\/group-chat-software\/"},{"issue":"1","key":"4852_CR28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1177\/1525822X02239569","volume":"15","author":"GW Ryan","year":"2003","unstructured":"Ryan GW, Bernard HR. Techniques to identify themes. Field methods. 2003;15(1):85\u2013109.","journal-title":"Field methods"},{"key":"4852_CR29","unstructured":"MAXQDA. Software for qualitative data analysis, 1989\u20132025, VERBI Software. Consult. Sozialforschung GmbH, Berlin, Germany."},{"issue":"5","key":"4852_CR30","doi-asserted-by":"publisher","first-page":"e027439","DOI":"10.1136\/bmjopen-2018-027439","volume":"9","author":"N Elkhadragy","year":"2019","unstructured":"Elkhadragy N, Ifeachor AP, Diiulio JB, Arthur KJ, Weiner M, Militello LG, et al. Medication decision-making for patients with renal insufficiency in inpatient and outpatient care at a US Veterans Affairs Medical Centre: a qualitative, cognitive task analysis. BMJ Open. 2019;9(5):e027439.","journal-title":"BMJ Open"},{"issue":"4","key":"4852_CR31","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jsps.2015.01.010","volume":"24","author":"LM Khan","year":"2016","unstructured":"Khan LM, Al-Harthi SE, Osman AM, Sattar MA, Ali AS. Dilemmas of the causality assessment tools in the diagnosis of adverse drug reactions. Saudi Pharm J. 2016;24(4):485\u201393.","journal-title":"Saudi Pharm J"},{"issue":"2","key":"4852_CR32","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"4852_CR33","doi-asserted-by":"publisher","first-page":"e28096","DOI":"10.1371\/journal.pone.0028096","volume":"6","author":"RM Gallagher","year":"2011","unstructured":"Gallagher RM, Kirkham JJ, Mason JR, Bird KA, Williamson PR, Nunn AJ, et al. Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool. PLoS ONE. 2011;6(12):e28096.","journal-title":"PLoS ONE"},{"issue":"7","key":"4852_CR34","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1197\/aemj.9.7.740","volume":"9","author":"GJ Kuhn","year":"2002","unstructured":"Kuhn GJ. Diagnostic errors. Acad Emerg Med. 2002;9(7):740\u201350.","journal-title":"Acad Emerg Med"},{"key":"4852_CR35","doi-asserted-by":"publisher","first-page":"154292","DOI":"10.1016\/j.jcrc.2023.154292","volume":"75","author":"RM Murphy","year":"2023","unstructured":"Murphy RM, Dongelmans DA, Kom IY, Calixto I, Abu-Hanna A, Jager KJ, et al. Drug-related causes attributed to acute kidney injury and their documentation in intensive care patients. J Crit Care. 2023;75:154292.","journal-title":"J Crit Care"},{"issue":"4","key":"4852_CR36","first-page":"177","volume":"5","author":"S Yazdani","year":"2017","unstructured":"Yazdani S, Hosseinzadeh M, Hosseini F. Models of clinical reasoning with a focus on general practice: A critical review. J Adv Med Educ Prof. 2017;5(4):177\u201384.","journal-title":"J Adv Med Educ Prof"},{"issue":"20","key":"4852_CR37","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1056\/NEJM198005153022003","volume":"302","author":"SG Pauker","year":"1980","unstructured":"Pauker SG, Kassirer JP. The threshold approach to clinical decision making. N Engl J Med. 1980;302(20):1109\u201317.","journal-title":"N Engl J Med"},{"issue":"2","key":"4852_CR38","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2215\/CJN.0000000000000044","volume":"18","author":"BR Griffin","year":"2023","unstructured":"Griffin BR, Wendt L, Vaughan-Sarrazin M, Hounkponou H, Reisinger HS, Goldstein SL, et al. Nephrotoxin Exposure and Acute Kidney Injury in Adults. Clin J Am Soc Nephrol. 2023;18(2):163\u201372.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"4852_CR39","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/phar.70071","volume":"45","author":"SL Kane-Gill","year":"2025","unstructured":"Kane-Gill SL. Kidney Damage Biomarkers: A Missing Piece of the Diagnostic and Management Puzzle for Acute Drug-Related Kidney Diseases. Pharmacotherapy. 2025;45(11):714\u201320.","journal-title":"Pharmacotherapy"},{"key":"4852_CR40","doi-asserted-by":"crossref","unstructured":"Cha\u00efbi K, Dreyfuss D, Gaudry S. Biomarkers and the prediction of acute kidney injury and renal replacement therapy initiation: a dream within a dream. Intensive Care Med. 2025.","DOI":"10.1007\/s00134-025-08254-9"},{"issue":"10","key":"4852_CR41","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1517\/14740338.2014.951328","volume":"13","author":"G Sidorenkov","year":"2014","unstructured":"Sidorenkov G, Navis G. Safety of ACE inhibitor therapies in patients with chronic kidney disease. Expert Opin Drug Saf. 2014;13(10):1383\u201395.","journal-title":"Expert Opin Drug Saf"},{"issue":"9","key":"4852_CR42","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.amjmed.2015.04.017","volume":"128","author":"H Yamout","year":"2015","unstructured":"Yamout H, Levin ML, Rosa RM, Myrie K, Westergaard S. Physician Prevention of Acute Kidney Injury. Am J Med. 2015;128(9):1001\u20136.","journal-title":"Am J Med"},{"issue":"4","key":"4852_CR43","doi-asserted-by":"publisher","first-page":"287","DOI":"10.5527\/wjn.v3.i4.287","volume":"3","author":"S Brachemi","year":"2014","unstructured":"Brachemi S, Boll\u00e9e G. Renal biopsy practice: What is the gold standard? World J Nephrol. 2014;3(4):287.","journal-title":"World J Nephrol"},{"issue":"6","key":"4852_CR44","doi-asserted-by":"publisher","first-page":"381","DOI":"10.5414\/CN108301","volume":"81","author":"MA Perazella","year":"2014","unstructured":"Perazella MA. Diagnosing drug-induced AIN in the hospitalized patient: a challenge for the clinician. Clin Nephrol. 2014;81(6):381\u20138.","journal-title":"Clin Nephrol"},{"issue":"10","key":"4852_CR45","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1681\/ASN.2015121377","volume":"27","author":"Y Xie","year":"2016","unstructured":"Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol. 2016;27(10):3153\u201363.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"4852_CR46","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","volume":"176","author":"B Lazarus","year":"2016","unstructured":"Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238\u201346.","journal-title":"JAMA Intern Med"},{"issue":"5","key":"4852_CR47","doi-asserted-by":"publisher","first-page":"380","DOI":"10.12788\/jhm.2735","volume":"12","author":"MA Perazella","year":"2017","unstructured":"Perazella MA. Diagnostic Testing in AKI: Let\u2019s Move the Field Forward. J Hosp Med. 2017;12(5):380\u20131.","journal-title":"J Hosp Med"},{"issue":"8","key":"4852_CR48","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/jamainternmed.2019.1755","volume":"179","author":"A Strasma","year":"2019","unstructured":"Strasma A, Kulkarni SA. Overuse of Urine Eosinophils in the Diagnosis of Acute Interstitial Nephritis: A Teachable Moment. JAMA Intern Med. 2019;179(8):1131\u20132.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"4852_CR49","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1186\/s13054-023-04720-2","volume":"27","author":"I Karimzadeh","year":"2023","unstructured":"Karimzadeh I, Barreto EF, Kellum JA, Awdishu L, Murray PT, Ostermann M, et al. Moving toward a contemporary classification of drug-induced kidney disease. Crit Care. 2023;27(1):435.","journal-title":"Crit Care"},{"issue":"5Part2","key":"4852_CR50","doi-asserted-by":"publisher","first-page":"397","DOI":"10.7326\/0003-4819-158-5-201303051-00006","volume":"158","author":"JLLL Kwan","year":"2013","unstructured":"Kwan JLLL, Sampson M, Shojania KG. Medication Reconciliation During Transitions of Care as a Patient Safety Strategy. Ann Intern Med. 2013;158(5Part2):397\u2013403.","journal-title":"Ann Intern Med"},{"issue":"1","key":"4852_CR51","first-page":"207","volume":"22","author":"N Mastellos","year":"2014","unstructured":"Mastellos N, Car J, Majeed A, Aylin P. Using information to deliver safer care: a mixed-methods study exploring general practitioners\u2019 information needs in North West London primary care. J Innov Health Inf. 2014;22(1):207\u201313.","journal-title":"J Innov Health Inf"},{"issue":"4","key":"4852_CR52","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/fcp.12758","volume":"36","author":"A Rey","year":"2022","unstructured":"Rey A, Gras-Champel V, Choukroun G, Masmoudi K, Liabeuf S. Risk factors for and characteristics of community- and hospital-acquired drug-induced acute kidney injuries. Fundam Clin Pharmacol. 2022;36(4):750\u201361.","journal-title":"Fundam Clin Pharmacol"},{"issue":"12","key":"4852_CR53","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1111\/jcpt.13811","volume":"47","author":"EC Polat","year":"2022","unstructured":"Polat EC, Koc A, Demirkan K. The role of the clinical pharmacist in the prevention of drug-induced acute kidney injury in the intensive care unit. J Clin Pharm Ther. 2022;47(12):2287\u201394.","journal-title":"J Clin Pharm Ther"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-04852-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04852-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04852-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:20:35Z","timestamp":1781637635000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-04852-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4852"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-04852-x","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"25 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. The Medical Ethics Committee provided a waiver from formal approval (W22_340 #22.412) since the LEAPfROG project, including all sub studies, does not fall within the scope of the Dutch Medical Research Involving Human Subjects Act.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ameen Abu-Hanna\n                      7\n                      , Annette ten Teije\n                      8\n                      , Birgit A. Damoiseaux-Volman\n                      7\n                      , Cornelis Boersma\n                      9\n                      , Dave A. Dongelmans\n                      10\n                      , David H. de Koning\n                      7\n                      , Frank van Harmelen\n                      8\n                      , Gerty Holla\n                      11\n                      , Heiralde Marck\n                      12\n                      , Giovanni Cin\u00e0\n                      7\n                      , Iacopo Vagliano\n                      7\n                      , Jan Pander\n                      13\n                      , Joanna E. Klopotowska\n                      1,2,3\n                      , Jurjen van der Schans\n                      9\n                      , Joris E. Lieverse\n                      1,2\n                      , Daniel Fern\u00e1ndez-Llaneza\n                      7\n                      , Romy M. P. Vos\n                      8\n                      , Menno Maris\n                      7\n                      , Izak Yasrebi-de Kom\n                      7\n                      , Kitty J. Jager\n                      7,14\n                      , Leonora van Drop-Grandia\n                      15\n                      , Linda Dusseljee-Peute\n                      1,2,4,5\n                      , Luuk B. Hilbrands\n                      16\n                      , Marcel S.G. Kwa\n                      17\n                      , Marieke A. R. Bak\n                      7\n                      , Mariette van den Hoven\n                      7\n                      , Martijn G. Kersloot\n                      18\n                      , Nicolette F. de Keizer\n                      7\n                      , Otto R. Maarsingh\n                      7\n                      , Paul Blank\n                      19\n                      , Piet Heingraaf\n                      20\n                      , Ren\u00e9e de Wildt\n                      21\n                      , Ron Herings\n                      7,22\n                      , Ron J. Keizer\n                      23\n                      , Ronald Cornet\n                      7\n                      , Ruben Boyd\n                      24\n                      , Sebastiaan L. Knijnenburg\n                      18\n                      , Sipke Visser\n                      25\n                      , Stephanie Medlock\n                      1,5,6\n                      , Stijn Gremmen\n                      26\n                      , Teun van Gelder\n                      27\n                      , Tjerk S. Heijmens Visser\n                      28\n                      , Vianda S. Stel\n                      7,29\n                      .\n                      1\n                      Department of Medical Informatics, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands\n                      2\n                      Amsterdam Public Health, Digital Health, Amsterdam, The Netherlands\n                      3\n                      Amsterdam Public Health, Quality of Care, Amsterdam, The Netherlands\n                      4\n                      Amsterdam UMC Location University of Amsterdam, Department of Medical Informatics, eHealth Living & Learning Lab, Meibergdreef 9, Amsterdam, the Netherlands\n                      5\n                      Amsterdam Public Health, Aging and Later Life, Amsterdam, The Netherlands\n                      6\n                      Amsterdam Public Health, Methodology, Amsterdam, The Netherlands\n                      7\n                      Amsterdam University Medical Center\n                      8\n                      Vrije Universiteit Amsterdam\n                      9\n                      Open Universiteit\n                      10\n                      Nationale Intensive Care Evaluatie foundation\n                      11\n                      Amsterdam Economic Board\n                      12\n                      Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie [KNMP] Geneesmiddelen Informatie Centrum\n                      13\n                      AstraZeneca\n                      14\n                      European Renal Association-European Dialysis and Transplantation Association [ERA-EDTA] Registry\n                      15\n                      Z-Index\n                      16\n                      Radboud University Medical Center\n                      17\n                      College ter Beoordeling van Geneesmiddelen\n                      18\n                      Castor\n                      19\n                      NWO\n                      20\n                      Pitts.AI\n                      21\n                      Dutch Kidney Association\n                      22\n                      PHARMO Institute for Drug Outcomes Research\n                      23\n                      InsightRX\n                      24\n                      IXA\n                      25\n                      Digital Health Link\n                      26\n                      Dutch Kidney Foundation\/Nierstichting\n                      27\n                      Leiden University Medical Center\n                      28\n                      CZ Health Insurance, Zorgverzekeraars Nederland\n                      29\n                      European Renal Association [ERA] Registry","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consortium Members"}}],"article-number":"231"}}